Results 171 to 180 of about 205,861 (285)

Pyrexia in juvenile dogs: a retrospective analysis of diagnosis and clinical features of 115 Australian cases

Australian Veterinary Journal, EarlyView.
Pyrexia is a non‐specific clinical sign associated with many diseases in dogs. This case series examines the final diagnoses, breed distribution and outcomes in dogs aged 18 months or under with pyrexia >24 h duration. Medical record databases of 11 Australian emergency and referral hospitals between 1st January 2020 and 31st January 2025 were searched
H Lobegeier, J Campo, C Cannon, P Bennett   +3 more
wiley   +1 more source

Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors

British Journal of Haematology, EarlyView.
Summary Immune checkpoint inhibitors (ICIs) have shown to be effective in the treatment of Hodgkin lymphoma (HL). ICI treatment is associated with the occurrence of a series of immune‐related adverse events (irAEs). We conducted an ambispective observational study on 96 patients with relapsed/refractory HL treated with ICIs to determine the incidence ...
Lisa Argnani, Vittorio Stefoni, Beatrice Casadei, Carla Pelusi, Valentina Lo Preiato, Uberto Pagotto, Anna Buganè, Cinzia Pellegrini, Alessandro Broccoli, Pier Luigi Zinzani   +9 more
wiley   +1 more source

NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts. [PDF]

Cancer Chemother Pharmacol
Nomura H, Suzuki T, Kojima T, Itoh K, Tsuji D.   +4 more
europepmc   +1 more source

Chronic neutropenia

Hematology, 2014
Ashley, Shaver, Kelly, Walkovich, Laurence, Boxer   +2 more
openaire   +2 more sources

Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants

British Journal of Haematology, EarlyView.
Summary Constitutional pathogenic variants in DDX41 predispose to myelodysplasia and acute myeloid leukaemia. Acquisition of subsequent somatic hits in the second allele is frequent, with notable recurrent variants at key hotspots. Sequencing of Deoxyribonucleic acid from blood/marrow of 239 patients with suspected/confirmed haematological malignancies
Andrew George, Elisabeth Rolf, Monika Domeradzka, Sara Ribeiro, Brittany Mills, April Hallett, Suzanne Macmahon, Paula Proszek, Ridwan Shaikh, Lina Yuan, Michael Hubank, Mikel Valganon Petrizan, Terri P. McVeigh, Jamshid S. Khorashad   +13 more
wiley   +1 more source

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia. [PDF]

ESMO Open
Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C, Bardia A.   +12 more
europepmc   +1 more source

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome

British Journal of Haematology, EarlyView.
Fostamatinib had 46% durable response, with 73% steroid reduction, in this multicentre retrospective study of refractory wAIHA/ES. Hypertension, gastrointestinal (GI) distress and neutropenia occurred in 23%. Only one patient required drug discontinuation and one patient dose reduction.
Jorge N. Ruiz Lopez, Lipei Shao, Debbie Jiang, Lawrence S. Bailey, Thejaswi Bikkani, Aaron Boothby, Donald C. Moore, Irina Murakhovskaya, Caroline I. Piatek, Mauricio Pineda‐Roman, Ping Jin, Jacqueline N. Poston, Moritz Stolla, David F. Stroncek, Krystalyn E. Hudson, James B. Bussel, Sandhya R. Panch   +16 more
wiley   +1 more source

Association Between a Shortage of Normal Saline and In-Hospital Outcomes Among Individuals With Febrile Neutropenia. [PDF]

J Pharm Technol
Stacks AE, Russell LA, Weeda ER.
europepmc   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

Neutropenic Tonsillar Ulcer as the Initial Presentation of Acute Myeloid Leukemia in a Young Woman: A Case Report. [PDF]

Cureus
Al Hassani M, Saleem A, Al Hassani Z, Al Hassani A, Farooqi MF.   +4 more
europepmc   +1 more source